Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers

Table 1 Outcome of transarterial chemoembolization in patients with hepatocellular carcinoma and different portal vein tumor thrombosis grades

First author, year	Patients (patients)	Treatment	PVTT Class (Vp)	Median survival time(mo)	1-yr survival rate	2-yr survival rate	3-yr survival rate	5-yr survival rate
Okazaki M, 1991	163	TACE	Vp 2 (48) Vp 3 (56) Vp 4 (59)	4.3 mo 4 mo 3.8 mo	-	-	-	-
Chung JW, 1995	83	TACE	Vp 3,4 (83)	6 mo	30%	18%	9%	-
Georgiades CS, 2005	32	TACE	Vp 3,4 (32)	9.5 mo	25%	-	-	-
Luo J, 2011	84	TACE	Vp 1,2 (40) Vp 3 (44)	10.2 mo 5.3 mo	30.9% 3.8%	9.2% 0%	-	-
Niu ZJ, 2012	115	TACE	Vp 1 (12) Vp 2 (52) Vp 3 (42) Vp 4 (9)	19 11 7.1 4	27.8%	6%	-	-
Peng ZW, 2012	402	TACE	Vp 1 (54) Vp 2 (136) Vp 3 (166) Vp 4 (46)	-	41.1% 37.9% 36.1% 30.4%	-	8.9% 6% 4.2% 4.3%	3.6% 0% 0% 0%
Ajit Y, 2014		TACE		6.2 mo	-	22%	-	-
Liu L, 2014	188	TACE	Vp 1,2 (98) Vp 3 (90)	6	38%	17%	3%	-
Liu PH, 2014	181	TACE	Vp 1,2 (181)	-	60%	-	42%	33%
Chern MC, 2014	50	TACE	Vp 1,2,3,4	6.2 mo (range, 1.7–50.9 mo)	22%	10%	8%	-
Tawada A, 2014	81	TACE	Vp 1,2,3,4	NA	45%	23%	20%	-
Ye JZ, 2014	338	TACE (86 patients)	Vp 1,2,3,4	7.0 mo	17.5%	0%	0%	-
Tan X, 2015	116	TACE (64 patients) TACE+PVE (52 patients)	Type I, II, III (according to Shi et al)	27.7 mo	60.9% 80.7%	41% 59%	25% 36.5%	0% 11.5%